DK1648904T3 - N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander - Google Patents
N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-liganderInfo
- Publication number
- DK1648904T3 DK1648904T3 DK04757294T DK04757294T DK1648904T3 DK 1648904 T3 DK1648904 T3 DK 1648904T3 DK 04757294 T DK04757294 T DK 04757294T DK 04757294 T DK04757294 T DK 04757294T DK 1648904 T3 DK1648904 T3 DK 1648904T3
- Authority
- DK
- Denmark
- Prior art keywords
- sulfonylheterocyclopyrrole
- hydroxytryptamine
- ligands
- alkylamine compounds
- alkylamine
- Prior art date
Links
- -1 alkylamine compounds Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49162203P | 2003-07-31 | 2003-07-31 | |
| PCT/US2004/023993 WO2005012311A1 (en) | 2003-07-31 | 2004-07-23 | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1648904T3 true DK1648904T3 (da) | 2007-10-22 |
Family
ID=34115532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04757294T DK1648904T3 (da) | 2003-07-31 | 2004-07-23 | N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7041695B2 (de) |
| EP (1) | EP1648904B1 (de) |
| JP (1) | JP2007500701A (de) |
| CN (1) | CN100443487C (de) |
| AT (1) | ATE370955T1 (de) |
| AU (1) | AU2004261606A1 (de) |
| BR (1) | BRPI0413158A (de) |
| CA (1) | CA2532382A1 (de) |
| DE (1) | DE602004008474T2 (de) |
| DK (1) | DK1648904T3 (de) |
| ES (1) | ES2290740T3 (de) |
| MX (1) | MXPA06000957A (de) |
| PL (1) | PL1648904T3 (de) |
| WO (1) | WO2005012311A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005012311A1 (en) * | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
| GB0403781D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical compounds |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| MX2007015772A (es) * | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| EP2053052A1 (de) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| AU2018257372B2 (en) | 2017-04-24 | 2022-06-02 | Bayer Aktiengesellschaft | Condensed bicyclic heterocyclic-compound derivatives as pest control agents |
| CN120289484B (zh) * | 2025-04-16 | 2026-04-10 | 聊城大学 | 一种吡咯烷酮并二氢异噁唑类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537974A1 (fr) * | 1982-12-16 | 1984-06-22 | Adir | Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| GB0016454D0 (en) * | 2000-07-04 | 2000-08-23 | Hoffmann La Roche | Thienopyrrolidinones |
| DE10063992A1 (de) | 2000-12-21 | 2002-07-04 | Max Planck Gesellschaft | Tryptophan-Analoga in Proteinen, Peptiden und peptidischen Leitstrukturen |
| ES2264994T3 (es) * | 2000-12-22 | 2007-02-01 | Wyeth | Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6. |
| US6730694B1 (en) * | 2001-07-20 | 2004-05-04 | Eli Lilly And Company | sPLA2 inhibitors |
| DK1455779T3 (da) * | 2001-12-20 | 2006-10-30 | Wyeth Corp | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander |
| TW200407127A (en) | 2002-08-21 | 2004-05-16 | Astrazeneca Ab | Chemical compounds |
| DE60318716T2 (de) * | 2002-08-21 | 2009-01-08 | Astrazeneca Ab | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren |
| WO2005012311A1 (en) * | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
-
2004
- 2004-07-23 WO PCT/US2004/023993 patent/WO2005012311A1/en not_active Ceased
- 2004-07-23 AT AT04757294T patent/ATE370955T1/de not_active IP Right Cessation
- 2004-07-23 PL PL04757294T patent/PL1648904T3/pl unknown
- 2004-07-23 MX MXPA06000957A patent/MXPA06000957A/es active IP Right Grant
- 2004-07-23 BR BRPI0413158-4A patent/BRPI0413158A/pt not_active IP Right Cessation
- 2004-07-23 AU AU2004261606A patent/AU2004261606A1/en not_active Withdrawn
- 2004-07-23 DK DK04757294T patent/DK1648904T3/da active
- 2004-07-23 CN CNB2004800210108A patent/CN100443487C/zh not_active Expired - Fee Related
- 2004-07-23 EP EP04757294A patent/EP1648904B1/de not_active Expired - Lifetime
- 2004-07-23 ES ES04757294T patent/ES2290740T3/es not_active Expired - Lifetime
- 2004-07-23 DE DE602004008474T patent/DE602004008474T2/de not_active Expired - Fee Related
- 2004-07-23 JP JP2006521964A patent/JP2007500701A/ja not_active Withdrawn
- 2004-07-23 CA CA002532382A patent/CA2532382A1/en not_active Abandoned
- 2004-07-30 US US10/909,092 patent/US7041695B2/en not_active Expired - Fee Related
-
2006
- 2006-02-01 US US11/344,765 patent/US7220756B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060160878A1 (en) | 2006-07-20 |
| BRPI0413158A (pt) | 2006-10-03 |
| JP2007500701A (ja) | 2007-01-18 |
| CN1826346A (zh) | 2006-08-30 |
| ES2290740T3 (es) | 2008-02-16 |
| DE602004008474D1 (de) | 2007-10-04 |
| PL1648904T3 (pl) | 2008-01-31 |
| US7041695B2 (en) | 2006-05-09 |
| US20050038088A1 (en) | 2005-02-17 |
| WO2005012311A1 (en) | 2005-02-10 |
| EP1648904B1 (de) | 2007-08-22 |
| CN100443487C (zh) | 2008-12-17 |
| DE602004008474T2 (de) | 2008-05-15 |
| EP1648904A1 (de) | 2006-04-26 |
| MXPA06000957A (es) | 2006-03-30 |
| AU2004261606A1 (en) | 2005-02-10 |
| CA2532382A1 (en) | 2005-02-10 |
| US7220756B2 (en) | 2007-05-22 |
| ATE370955T1 (de) | 2007-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04005886A (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6. | |
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| SE0201635D0 (sv) | Novel compounds | |
| CY1108738T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου | |
| BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| BR0311591A (pt) | 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6 | |
| DK1853602T3 (da) | Kemiske forbindelser | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| TW200505904A (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
| DE602005016929D1 (de) | Liganden für den cannabinoidrezeptoren | |
| EA200501504A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
| CR8644A (es) | Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| MXPA06000701A (es) | Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6. | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| PL1648904T3 (pl) | Związki N-sulfonyloheterocyklopirolioalkiloaminowe jako ligandy 5-hydroksytryptaminy-6 | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| EP1599201A4 (de) | Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| NO20080937L (no) | Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander |